

RENALYTIX AI.

6 September 2019

Renalytix AI plc
("RenalytixAI" or the "Company")

Posting of Annual Report & Accounts and Notice of AGM

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical *in vitro* diagnostics for kidney disease, confirms that the Annual Report and Accounts for the period ended 30 June 2019 ("2019 Annual Report"), the Notice of the Annual General Meeting contained therein (the "Notice of AGM") and forms of proxy are being posted to shareholders today and are available now on the Company's website in accordance with AIM Rule 20:

<https://renalytixai.com/investors/annual-half-year-reports/>

The AGM is to be held on 30 September 2019 at 11am at the offices of Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD.

For further information, please contact:

Renalytix AI plc
James McCullough, CEO

www.renalytixai.com
Via Walbrook PR

Stifel (Nominated Adviser & Joint Broker)
Alex Price / Jonathan Senior / Ben Maddison

Tel: 020 7710 7600

N+1 Singer (Joint Broker)
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com